3.44

2.55% -0.09

Galectin Therapeutics Inc (GALT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.53

Aprire:

$3.5

Volume 24 ore:

388.20K

Relative Volume:

0.61

Capitalizzazione di mercato:

$346.92M

Reddito:

Utile/perdita netta:

$-26.25M

Rapporto P/E:

-8.3923

EPS:

-0.4099

Flusso di cassa netto:

$-20.05M

1 W Prestazione:

-0.29%

1M Prestazione:

-35.58%

6M Prestazione:

+24.64%

1 anno Prestazione:

-8.51%

Intervallo 1D:

$3.20

$3.5462

Intervallo di 1 settimana:

$3.02

$3.56

Portata 52W:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Nome

Galectin Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (604)

Telefono

678-620-3186

Indirizzo

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Dipendente

Cinguettio

@galectingalt

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GALT Galectin Therapeutics Inc	3.44	316.67M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-17	Ripresa	H.C. Wainwright	Buy
2020-08-13	Reiterato	H.C. Wainwright	Buy
2019-02-13	Iniziato	B. Riley FBR	Buy
2017-12-07	Reiterato	H.C. Wainwright	Buy
2017-11-28	Reiterato	H.C. Wainwright	Buy
2017-10-19	Iniziato	ROTH Capital	Buy
2017-03-30	Aggiornamento	H.C. Wainwright	Neutral → Buy
2016-10-03	Downgrade	FBR & Co.	Outperform → Mkt Perform
2016-09-29	Downgrade	H.C. Wainwright	Buy → Neutral
2016-09-28	Downgrade	ROTH Capital	Buy → Sell
2016-03-28	Ripresa	H.C. Wainwright	Buy
2015-09-21	Iniziato	H.C. Wainwright	Buy
2014-08-01	Downgrade	Aegis Capital	Buy → Hold
2014-07-30	Reiterato	MLV & Co	Buy
2014-07-29	Reiterato	MLV & Co	Buy
2014-04-02	Reiterato	MLV & Co	Buy
2014-02-10	Reiterato	Aegis Capital	Buy
2014-01-09	Reiterato	Aegis Capital	Buy
2013-12-03	Iniziato	MLV & Co	Buy
2013-08-19	Reiterato	Aegis Capital	Buy

Mostra tutto

Galectin Therapeutics Inc Borsa (GALT) Ultime notizie

Aug 15, 2026

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aug 15, 2026

Aug 14, 2026

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Aug 14, 2026

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart

Aug 14, 2026

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView

Aug 14, 2026

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com

Aug 14, 2026

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative

Aug 14, 2026

GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 10, 2026

Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 07, 2026

Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelHagopian Line - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et

Aug 06, 2026

Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat

Aug 06, 2026

Aug 05, 2026

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail

Aug 05, 2026

Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India

Aug 05, 2026

Aug 04, 2026

Galectin chairman converts $105.8 million debt to equity - Investing.com

Aug 04, 2026

Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan

Aug 04, 2026

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative

Aug 04, 2026

Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan

Aug 04, 2026

Aug 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review

Aug 03, 2026

Aug 02, 2026

Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesDemand Zone - dars.gov.et

Aug 02, 2026

Jul 31, 2026

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Jul 31, 2026

Jul 27, 2026